Sugi Predict

Sugi Predict / Compounds / SCHEMBL214341

SCHEMBL214341

SCHEMBL214341

Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)ccc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.68
▸ ALDH1A1 P00352 5/20 0.68
▸ LMNA P02545 2/20 0.68
▸ HPGD P15428 1/20 0.59
▸ MET P08581 1/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ GPR119 Q8TDV5 2/20 0.49
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ PDK2 Q15119 1/20 0.48
▸ SIRT6 Q8N6T7 2/20 0.47
▸ ADAMTS5 Q9UNA0 1/20 0.47
▸ DCTPP1 Q9H773 1/20 0.46
▸ TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29803559 1.00 MAPT (0.68) MAPTALDH1A1LMNAHPGDMET
SCHEMBL16665290 0.91 ALDH1A1 (0.68) MAPTALDH1A1LMNAHPGDMET
SCHEMBL16270620 0.90 MAPT (0.71) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL29858317 0.90 MAPT (0.71) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL1106913 0.88 MAPT (0.68) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL30307835 0.88 MAPT (0.68) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL31487617 0.87 MAPT (0.67) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL15863535 0.87 ALDH1A1 (0.67) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL16569830 0.87 MAPT (0.67) MAPTALDH1A1LMNAMETSMN1; SMN2
SCHEMBL216810 0.87 MAPT (0.67) MAPTALDH1A1LMNAMETSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 — — EP disclosed
WO-2024155112-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS UPPTHERA, INC. (KR) 2024-07-25 — — WO disclosed
WO-2024141052-A1 ESTROGEN-RECEPTOR MODULATOR AND USE THEREOF 江苏威凯尔医药科技有限公司 2024-07-04 — — WO disclosed
CN-118271284-A Estrogen receptor modulators and uses thereof 江苏威凯尔医药科技有限公司 2024-07-02 — — CN disclosed
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-10-26 — — US disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 — — WO disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 — — WO disclosed
EP-3816160-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY Reborna Biosciences, Inc. (JP) 2021-05-05 — — EP disclosed
US-8440663-B2 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2013-05-14 — — US disclosed
US-8299023-B2 Neuropeptide-2 receptor (Y-2R) agonists HOFFMANN-LA ROCHE INC. (US) 2012-10-30 — — US disclosed
US-6555541-B1 P2X7 receptor antagonists for treatment of inflammatory respiratory system disorders such as asthma; for example, 2-(3,4-Difluorophenylamino)-N-(2-methyl-5-piperazin-1-yl-methyl-phenyl) -acetamide, trihydrochloride ASTRAZENECA UK LIMITED (GB) 2003-04-29 — — US disclosed
US-20030073700-A1 New indole derivatives with 5HT6 receptor affinity SYNTEX (U.S.A.) LLC, NAME CHANGE TO ROCHE PALO ALTO LLC 2003-04-17 — — US disclosed
WO-2002098857-A1 NEW INDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY F. HOFFMANN-LA ROCHE AG (CH) 2002-12-12 — — WO disclosed
US-6492355-B1 Adamantane derivatives ASTRAZENECA AB (SE) 2002-12-10 — — US disclosed
CN-1353702-A Adamantane derivative ASTRAZENECA AB (SE) 2002-06-12 — — CN disclosed
CN-1351598-A Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions ASTRAZENECA AB (SE) 2002-05-29 — — CN disclosed
EP-1185522-A1 SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca AB (SE) 2002-03-13 — — EP disclosed
EP-1171432-A1 ADAMANTANE DERIVATIVES AstraZeneca AB (SE) 2002-01-16 — — EP disclosed
WO-2000071529-A1 SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS ASTRAZENECA AB (SE) 2000-11-30 — — WO disclosed
WO-2000061569-A1 ADAMANTANE DERIVATIVES ASTRAZENECA AB (SE) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 MAPT 940/4885ALDH1A1 2251/4885LMNA 2982/4885
US-20030073700-A1 New indole derivatives with 5HT6 receptor affinity HTR6, HTR5A, HTR7 MAPT 3421/4885ALDH1A1 1394/4885LMNA 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.